Elizabeth Phillips, MD
Infectious Disease · Nashville, TNNPI 1952737439
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $71,008 of the $71,283 with a category attached, or 99.6%. Janssen Research & Development, LLC accounts for 80.6% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $23,315, more than ten times the $2,058 reported in 2019. Among infectious disease clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 20 payments — averaging $3564.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$57K
- Regeneron$4K
- Astrazeneca UK Limited$4K
- Biocryst Pharmaceuticals, Inc.$4K
- Vertex$1K
- Grifols USA, LLC$115
- plus $161 from 2 others
Across 1 payment — averaging $175.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$176
What the payments were for
- Consulting fees$71,008100%
- Food & beverage$2760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 9 | $57,453 |
| Regeneron | 2 | $4,125 |
| Astrazeneca UK Limited | 2 | $4,000 |
| Biocryst Pharmaceuticals, Inc. | 3 | $4,000 |
| Vertex | 1 | $1,430 |
| Grifols USA, LLC | 1 | $115 |
| Edwards Lifesciences | 1 | $103 |
| Medivators Inc. | 1 | $58 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$4,000
- Xembify$115
- SAPIEN 3 Ultra RESILIA$103
How this compares
$71,283 in reported general payments places this provider in the 95th percentile of 156 infectious disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Citalopram HbrCitalopram Hydrobromide | 11 | $64 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Nashville
- John KoetheNashville$91K
- Kassem BourgiNashville$34K
- Celestine WanjallaNashville$24K
- Sean KellyNashville$17K
- David AronoffNashville$17K
- William SchaffnerNashville$16K
- Juli HortonNashville$14K
- Maricar MalinisNashville$14K
- Paul BryantNashville$12K
- Christina FiskeNashville$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.